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Beta blockersAbstract Background: Post-operative atrial fibrillation (POAF) is amongst the most common
complications following cardiac surgery. Current guidelines recommend oral beta-blockers as a
first-line medication to prevent POAF. However, the ideal choice of beta-blocker is unclear, making
a comprehensive review crucial. We aimed to provide a clinically useful summary of the results of a
multiple-treatment meta-analysis of randomized controlled trials (RCT). Methods and Results: A
MEDLINE/PubMed search was conducted to identify eligible RCTs. Efficacy (POAF prevention
rate) and acceptability (dropout for side effect rate) outcomes were investigated. A frequentist
approach to network meta-analysis using the graph-theoretical method was implemented to obtain
network estimates. A total of 16 trials were included in the final analysis and 4727 subjects were
investigated. Network estimates showed that betaxolol (OR 0.36; 95%CI 0.25–0.52), carvedilol
(OR 0.36; 95%CI 0.23–0.58) and sotalol (OR 0.38; 95%CI 0.30–0.50) were more effective than pro-
pranolol (OR 0.51; 95%CI 0.27–0.95), metoprolol (OR 0.72; 95%CI 0.58–0.90) and atenolol (OR
0.81; 95%CI 0.42–1.56) in reducing the incidence of POAF when compared to placebo. Amongst
beta-blockers investigated, carvedilol showed the best safety profile being associated with the lowest
risk of patient dropped out for side effect (OR 1.14; 955CI 0.36–3.61). No evidence of heterogeneity/
inconsistency was found in the whole network for both efficacy (P= 0.8) and acceptability
(P= 0.4) outcomes. Conclusion: Overall, carvedilol was found to be effective in preventing POAF
while maintaining a good safety profile.
 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of Egyptian Society of
Cardiology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
90 M. Zeinah et al.1. Introduction
Post-operative atrial fibrillation (POAF) is amongst the most
common complications of cardiac surgery with reported inci-
dence of 30% after coronary artery bypass graft, 40% after
valve surgery, and 50% after combined procedures.1 POAF
has been shown to increase operative morbidity, including
stroke1,2 and has been associated with an increased length
and costs of hospitalization. Furthermore, POAF may nega-
tively affect late outcomes.3
The impact of POAF on patient outcomes has prompted
much investigation into the optimal methods for the preven-
tion and treatment of this complication.4 There has been con-
siderable interest in pharmacological prophylaxis against atrial
fibrillation occurring after cardiac surgery.4
Although many approaches have been attempted,4 current
American Heart Association/American College of Cardiology
and European Society of Cardiology guidelines recommend
oral beta-blockers as a first-line medication to prevent POAF
after cardiac surgery.5,6 However, pharmacological character-
istics differ considerably between oral beta-blockers and
despite previous meta-analyses,7–9 there remains confusion
about the potential superiority as well as the safety profile ofFigure 1 A flowchart showing datindividual agents making a comprehensive, updated review
important.
We report an overview of all randomized controlled trials
(RCTs) that compared oral beta-blockers in terms of efficacy
and acceptability in the prevention of POAF. We used
mixed-treatment comparisons10 (so-called network meta-
analysis) to obtain a comprehensive benefit-risk comparison11
of beta-blockers used in the prevention of POAF. We aimed to
provide a clinically useful summary of the results of the
multiple-treatment meta-analysis that can be used to guide
treatment decisions.
2. Methods
2.1. Design
The present review was performed according to the Cochrane
Collaboration and PRISMA statements.12,13
2.2. Search
A MEDLINE/PubMed search was conducted in June 2014
using the keywords ‘‘beta-blocker,” ‘‘post-operative atriala-collection and review process.
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‘‘randomised.” In addition, Google Scholar, The Cochrane
Library, and Scopus were also searched for pertinent citations.
2.3. Selection
Study selection was performed by two independent reviewers
(UB, CN), with divergences resolved by consensus. Citations
were first scanned at the title/abstract level. Short-listed studies
were then retrieved in full-text.
2.4. Inclusion and exclusion criteria
Articles were included if they reported an RCT that compares
the efficacy of oral beta-blockers to a placebo or another oral
beta-blocker. Trials were the control arm received another
drug (such as amiodarone), or no treatment was excluded from
this study. For trials including more than two arms, only
groups receiving oral beta-blockers or placebo were consid-
ered. When several publications reported on the same trial,
the largest sample size comparison was selected.
2.5. Abstraction and appraisal
Data abstraction and study appraisal were performed by two
independent reviewers (UB, CN). Key study and patient char-
acteristics were extracted, including efficacy (POAF incidence)
and safety outcomes (study drug withdrawal for side effects).
2.6. Analysis
Number of events in each arm was used to compute individual
study log Odds Ratio (OR) and standard error for the efficacy
and safety end-points. A frequentist approach to network
meta-analysis using the graph-theoretical method was
implemented to obtain network estimates.14 As in pairwise
meta-analysis, the Q statistic was estimated to measure the
deviation from consistency.15,16 A design-based decomposition
of Cochran’s Q was used for assessing the homogeneity in the
whole network, the homogeneity within designs, and the
homogeneity/consistency between designs.
All the analyses were conducted using R, version 3.1.0
and netmeta package (Gerta Ru¨cker, Guido Schwarzer,
Ulrike Krahn and Jochem Ko¨nig 2014. netmeta: Network
meta-analysis with R.R package version 0.5–0. http://CRAN.
Rproject.org/package = netmeta).Figure 2 Network of eligible comparisons for the multiple-
treatment meta-analysis for efficacy (postoperative atrial fibrilla-
tion prevention rate). The width of the lines is proportional to the
number of trials comparing each pair of treatments (inverse
standard error). The network of eligible comparisons for accept-
ability (dropout rate for side effect) analysis is similar. (ate =
atenolol, beta = betaxolol, car = carvedilol, met = metoprolol,
plac = placebo, pro = propranolol, sot = sotalol.)3. Results
The electronic searches yielded 140 potentially relevant studies,
of which 110 potentially eligible articles were reviewed after
duplicates were removed (Fig. 1). After screening the remain-
ing articles and selecting those that met our criteria, we
included 16 trials17–32 published between 1990 and 2013 for
the multiple-treatment meta-analysis investigating the follow-
ing 6 oral beta-blocker regimes in the prevention of
POAF: atenolol,27,32 betaxolol,22 carvedilol,17,21,23,28 meto-
prolol,17–19,21–25,28 propranolol30 and sotalol.18,20,24,26,27,29–31
Fig. 2 shows the network of eligible comparisons for
the multiple-treatments meta-analysis. An overview of thecharacteristics of the trials included is reported in Table 1. A
total of 11 trials enrolled only patients undergoing isolated
CABG while the remaining 5 included patients undergoing
concomitant valvular surgery. Twelve trials used continuous
telemetry to monitor the incidence of POAF. Overall, 5199
individuals were randomly assigned to one of the 7 beta-
blocker regimes and were included in the multiple-treatments
meta-analysis. 4727 were included in the acceptability network
meta-analysis. Median daily doses administered were as fol-
lows: atenolol 50 mg, betaxolol 20 mg, carvedilol 25 mg, meto-
prolol 125 mg, propranolol 60 mg, and sotalol 170 mg.
Network estimates showed that betaxolol (OR 0.36; 95%CI
0.25–0.52), carvedilol (OR 0.36; 95%CI 0.23–0.58) and sotalol
(OR 0.38; 95%CI 0.30–0.50) were more effective than propra-
nolol (OR 0.51; 95%CI 0.27–0.95), metoprolol (OR 0.72; 95%
CI 0.58–0.90) and atenolol (OR 0.81; 95%CI 0.42–1.56) in
reducing the incidence of POAF when compared to placebo
(Fig. 3, left).
No evidence of heterogeneity/inconsistency was found in
the whole network (Q= 6.95; P= 0.8), within designs
(Q= 4.91; P= 0.6) and between designs (Q= 2.04; P= 0.7).
With regard to the safety profile, all beta-blockers investi-
gated showed a trend towards an higher risk for drug discon-
tinuation due to side-effects but metoprolol only significantly
increased the risk of drug withdrawal when compared to pla-
cebo. Amongst beta-blockers investigated, carvedilol showed
the best safety profile being associated with the lowest risk of
patient dropped out for side effect (Fig. 3, right). No evidence
of heterogeneity/inconsistency was found in the whole network
(Q= 6.2; P= 0.4), within designs (Q= 2.5; P= 0.4) and
between designs (Q= 3.68; P= 0.2).
Head to head comparison for the effectiveness and safety
outcomes amongst the 6 beta-blockers investigated is reported
in Fig. 4.
Table 1 Summary of characteristics of studies included in this meta-analysis. (AF: atrial fibrillation, CABG: coronary artery bypass grafting; ECG: electrocardiogram; NK not
known).
Study Size Mean
age
%
Female
Active
treatment
Control
Group
Maximum
daily dose
Time of treatment Definition of AF ECG monitoring Surgery type
Acikel 2008 110 60 28 Carvedilol Metoprolol Metoprolol
100 mg
3 d pre-operatively,
discontinued
on the morning of
surgery
AFP 30 s Continuous ECG CABG
Carvedilol
25 mg
Auer 2004 253 65 40 Metoprolol,
Sotalol
Placebo Metoprolol
100 mg
24–48 h pre-operatively AF > 5 min Continuous ECG CABG, valves
Sotalol
240 mg
Connolly 2003 1000 NK NK Metoprolol Placebo Metoprolol
150 mg
Post-operatively for
14 days
NK NK CABG, valves
Gomes 1999 85 65 36 Sotalol Placebo Sotalol
240 mg
24–48 h pre-operatively
up to post-operative day
4
AFP 30 min Continuous ECG CABG, valves
Haghjoo 2007 120 61 47 Carvedilol Metoprolol Carvedilol
50 mg
10 d pre-operatively AF > 5 min Continuous ECG CABG
Metoprolol
100 mg
Iliuta 2009 1352 NK NK Betaxolol Metoprolol Betaxolol
20 mg
2 d pre-operatively and
at least 10d post-
operatively
NK Continuous ECG CABG
Metoprolol
200 mg
Ozaydin 2013 311 NK NK Carvedilol Metoprolol Metoprolol
200 mg
7 d pre-operatively AF > 5 min Continuous ECG CABG, valves
Carvedilol
25 mg
Parikka 1998 191 NK NK Sotalol Metoprolol Metoprolol
150 mg
1 d post-operatively Sustained AFP 15 min Continuous ECG CABG
Sotalol
240 mg
Paull 1997 100 63.4 11 Metoprolol Placebo Metoprolol
200 mg
24 h post-operatively AF > 15 min Continuous ECG CABG
Pfisterer 1997 255 NK NK Sotalol Placebo Sotalol
160 mg
2 h pre-operatively Any detectable AF Continuous ECG CABG, valves
Sanjuan 2004 253 66 NK Sotalol Atenolol Atenolol
50 mg
1d pre-operatively AFP 10 min Continuous ECG CABG
Sotalol
160 mg
Shahzamani 2011 60 NK 37 Carvedilol Metoprolol Carvedilol
25 mg
14 d pre-operatively NK NK CABG
Metoprolol
200 mg
Suttorp 1991 300 NK NK Sotalol Placebo Sotalol
240 mg
4–6 h post-operatively AF Continuous ECG CABG
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Current American College of Cardiology (ACC)/American
Heart Association (AHA) and European Society of Cardiol-
ogy (ESC) guidelines,5,6 strongly recommend oral beta-
blockers to prevent POAF in patients undergoing cardiac
surgery.
One problem associated with the prophylactic use of beta-
blockers to prevent POAF is that the majority of patients
who do not develop POAF would still be vulnerable to the
possible side effects.33 Therefore there is an urgent need to
identify which beta-blocker amongst the current alternatives
has the best benefit-risk profile.
Our analysis was based on 16 studies including 5199 indi-
viduals randomly assigned to 7 different oral beta-blockers
or matching placebos. Our findings will help to guide clinicians
when it comes to choosing a beta-blocker to use for the preven-
tion of POAF.
The beta-blockers investigated differ clinically and statisti-
cally. For the prevention of POAF, betaxolol, carvedilol and
sotalol were more effective than propranolol, metoprolol and
atenolol. On the other hand, carvedilol was found to be more
acceptable than other beta-blockers because of its relative
safety. Therefore carvedilol was a compromise strategy being
an effective and safe alternatives.
The mechanisms underlying the better benefit-risk profile of
carvedilol in the prevention of POAF are still unknown. There
is now an increasing body of evidence that oxidative stress,34
inflammation,35,36 and increased sympathetic activation37 are
involved in the pathogenesis of POAF. Carvedilol is a beta-
blocker with antioxidant and anti-inflammatory proper-
ties.38,39 Moreover, carvedilol may have direct antiarrhythmic
effect through electrophysiological traits, since it blocks multi-
ple cationic channels (Na+, K+, and Ca2+).39 In addition,
numerous trials indicate that carvedilol is better than conven-
tional beta 1-selective beta-blockers in reducing sympathetic
activation, a risk factor for atrial fibrillation.39 From a patho-
physiological point of view, it is plausible that the abovemen-
tioned properties of carvedilol might result in the favourable
effect on the prevention of POAF with a lower beta-
blockage. This could be the reason for better tolerability, hence
reducing the risk of side-effects. Several potential study limita-
tions should be considered. Most trials included in our analysis
did not report adequate information about randomization and
allocation concealment, and this might undermine the validity
of overall findings. Most trials included a relatively small num-
ber of patients, and not all studies included the same covariates
(type of operation, on-pump vs. off pump bypass surgery, con-
comitant medications). Additionally, the present network
meta-analysis included a moderate number of trials (n= 16),
which makes it difficult to conduct subgroup analyses. Unfor-
tunately, in some of these trials, patients assigned to placebo
who have previously been on beta-blockade probably suffered
from beta-blocker withdrawal, thus causing a bias against the
placebo groups. In fact, patients who have used preoperative
beta-blockers that are withdrawn after surgery seem to be at
a particularly high risk of POAF. Finally, various dosages of
the individual agents were used with different times of
administration.
In conclusion, our analysis suggests that carvedilol is candi-
date to be the preferred beta-blockers in terms of efficacy and
Figure 3 Forest plot for efficacy (left) and acceptability (right) of the 6 beta-blockers compared to placebo. (ate = atenolol,
beta = betaxolol, car = carvedilol, met = metoprolol, plac = placebo, pro = propranolol, sot = sotalol.)
Figure 4 Efficacy and acceptability of the 6 beta-blockers. Drugs are reported in alphabetical order. Results are the ORs in the column
defining treatment compared with the ORs in the row defining treatment. For efficacy, ORs higher than 1 favour the column-defining
treatment. For acceptability, ORs higher than 1 favour the column-defining treatment. To obtain ORs for comparisons in the opposite
direction, reciprocals should be taken. Significant results are in bold and underscored.
94 M. Zeinah et al.acceptability in the prevention of POAF and should be used as
standard therapy. Current evidence suggests that beta-blocker
prophylaxis is more effective when initiated preoperatively
rather than postoperatively5,6 and reinstitution of beta-
blockers after surgery has been associated with a reduction
of POAF.5,6
In addition, carvedilol should be considered as the standard
comparator in phase III trials to increase the real-world appli-
cability of the results. Furthermore, the need for new treatment
to show either greater efficacy or acceptability than an existing
standard therapy would serve as a disincentive to the develop-
ment of alternative agents that offer little clinical benefit with
increased costs.
Conflict of interest
No conflict to disclose.
References
1. Shantsila E, Watson T, Lip GY. Atrial fibrillation post-cardiac
surgery: changing perspectives. Curr Med Res Opin
2006;22:1437–41, Matched ISSN: 0300-7995 (View via PubMed)
Linked.
2. Mathew JP, Parks R, Savino JS, Friedman AS, Koch C, Mangano
DT, et al. Atrial fibrillation following coronary artery bypass graftsurgery: predictors, outcomes, and resource utilization. Multicen-
ter Study of Perioperative Ischemia Research Group. JAMA
1996;276:300–6, Matched ISSN: 0098-7484 (View via PubMed)
Linked.
3. Filardo G, Hamilton C, Hebeler Jr RF, Hamman B, Grayburn P.
New-onset postoperative atrial fibrillation after isolated coronary
artery bypass graft surgery and long-term survival. Circ Cardio-
vasc Qual Outcomes 2009;2:164–9, Matched ISSN: 1941-7705
(View via PubMed) Linked.
4. Burgess DC, Kilborn MJ, Keech AC. Interventions for prevention
of post-operative atrial fibrillation and its complications after
cardiac surgery: a meta-analysis. Eur Heart J 2006;27:2846–57,
Matched ISSN: 0195-668X (View via PubMed) Linked.
5. European Heart Rhythm Association; European Association for
Cardio-Thoracic Surgery Camm AJ, Kirchhof P, Lip GY,
Schotten U, Savelieva I, Ernst S, et al. Guidelines for the
management of atrial fibrillation: the task force for the manage-
ment of atrial fibrillation of the European Society of Cardiology
(ESC). Eur Heart J 2010;31:2369–429, Matched ISSN: 0195-668X
(View via PubMed) Linked.
6. Fuster V, Ryde´n LE, Cannom DS, Crijns HJ, Curtis AB,
Ellenbogen KA, et al. Guidelines for the management of patients
with atrial fibrillation: a report of the American College of
Cardiology Foundation/American Heart Association Task Force
on practice guidelines. Circulation 2006;2011(123):e269–367,
Matched ISSN: 0009-7322 (View via PubMed) Linked.
7. Kerin NZ, Jacob S. The efficacy of sotalol in preventing
postoperative atrial fibrillation: a meta-analysis. Am J Med
2011;124, 875.e1–9.
Which beta-blocker should be used for the prevention of postoperative atrial fibrillation in cardiac surgery? 958. Di Nicolantonio JJ, Beavers CJ, Menezes AR, Lavie CJ, O’Keefe
P, Meier P, et al. Meta-analysis comparing carvedilol versus
metoprolol for the prevention of postoperative atrial fibrillation
following coronary artery bypass grafting. Am J Cardiol
2014;113:565–9, Matched ISSN: 0002-9149 (View via PubMed)
Linked.
9. Wang HS, Wang ZW, Yin ZT. Carvedilol for prevention of atrial
fibrillation after cardiac surgery: a meta analysis. PLoS One
2014;9:e94005, Matched ISSN: 1932-6203 (View via PubMed)
Linked.
10. Cipriani A, Furukawa TA, Salanti G, Geddes JR, Higgins JP,
Churchill R, et al. Comparative efficacy and acceptability of 12
new-generation antidepressants: a multiple-treatments meta-anal-
ysis. Lancet 2009;373:746–58, Matched ISSN: 0140-6736 (View via
PubMed) Linked.
11. Postmus D, Tervonen T, van Valkenhoef G, Hillege HL, Buskens
E. A multi-criteria decision analysis perspective on the health
economic evaluation of medical interventions. Eur J Health Econ
2013(July 11) Epub ahead of print Matched ISSN: 1618-7598
(View via PubMed) Linked.
12. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC,
Ioannidis JP, et al. The PRISMA statement for reporting
systematic reviews and meta-analyses of studies that evaluate
health care interventions: explanation and elaboration. Ann Intern
Med 2009;151:W65–94, Matched ISSN: 0003-4819 (View via
PubMed) Linked.
13. Savovic´ J, Weeks L, Sterne JA, Turner L, Altman DG, Moher D,
et al. Evaluation of the Cochrane Collaboration’s tool for
assessing the risk of bias in randomized trials: focus groups,
online survey, proposed recommendations and their implementa-
tion. Syst Rev 2014;3:37, Matched ISSN: 0731-7239 (View via
PubMed) Linked.
14. Ru¨cker G. Network meta-analysis, electrical networks and graph
theory. Res Synth Methods 2012;3:312–24 (View via PubMed)
Linked.
15. Higgins JPT, Jackson D, Barrett JK, Lu G, Ades AE, White IR.
Consistency and inconsistency in network meta-analysis: concepts
and models for multi-arm studies. Res Synth Methods
2012;3:98–110 (View via PubMed) Linked.
16. Krahn U, Binder H, Ko¨nig J. A graphical tool for locating
inconsistency in network metaanalyses. BMC Med Res
Methodol 2013;13:35, Matched ISSN: 1471-2288 (View via
PubMed) Linked.
17. Acikel S, Bozbas H, Gultekin B, Aydinalp A, Saritas B, Bal U,
et al. Comparison of the efficacy of metoprolol and carvedilol for
preventing atrial fibrillation after coronary bypass surgery. Int J
Cardiol 2008;126:108–13, Matched ISSN: 0167-5273 (View via
PubMed) Linked.
18. Auer J, Weber T, Berent R, Puschmann R, Hartl P, Ng CK, et al.
Study of prevention of postoperative atrial fibrillation. A com-
parison between oral antiarrhythmic drugs in the prevention of
atrial fibrillation after cardiac surgery: the pilot study of preven-
tion of postoperative atrial fibrillation (SPPAF), a randomized,
placebo-controlled trial. Am Heart J 2004;147:636–43, Matched
ISSN: 0002-8703 (View via PubMed) Linked.
19. Connolly SJ, Cybulsky I, Lamy A, Roberts RS, O’brien B, Carroll
S, et al. Beta-Blocker Length Of Stay (BLOS) study. Double-blind,
placebo-controlled, randomized trial of prophylactic metoprolol
for reduction of hospital length of stay after heart surgery: the
beta-Blocker Length Of Stay (BLOS) study. Am Heart J
2003;145:226–32, Matched ISSN: 0002-8703 (View via PubMed)
Linked.
20. Gomes JA, Ip J, Santoni-Rugiu F, Mehta D, Ergin A, Lansman S,
et al. Oral sotalol reduces the incidence of postoperative atrial
fibrillation in coronary artery bypass surgery patients: a random-
ized, double-blind, placebo-controlled study. J Am Coll Cardiol
1999;34:334–9, Matched ISSN: 0735-1097 (View via PubMed)
Linked.21. Haghjoo M, Saravi M, Hashemi MJ, Hosseini S, Givtaj N,
Ghafarinejad MH, et al. Optimal beta-blocker for prevention of
atrial fibrillation after on-pump coronary artery bypass graft surgery:
carvedilol versusmetoprolol.HeartRhythm 2007;4:1170–4,Matched
ISSN: 1547-5271 (View via PubMed) Linked.
22. Iliuta L, Christodorescu R, Filpescu D, Moldovan H, Radulescu
R, Vasile R. Prevention of perioperative atrial fibrillation with
betablockers in coronary surgery: betaxolol versus metoprolol.
Interact Cardiovasc Thorac Surg 2009;9:89–93, Matched ISSN:
1569-9293 (View via PubMed) Linked.
23. Ozaydin M, Icli A, Yucel H, Akcay S, Peker O, Erdogan D, et al.
Metoprolol vs. carvedilol or carvedilol plus N-acetyl cysteine on
post-operative atrial fibrillation: a randomized, double-blind,
placebo-controlled study. Eur Heart J 2013;34:597–604, Matched
ISSN: 0195-668X (View via PubMed) Linked.
24. Parikka H, Toivonen L, Heikkila¨ L, Virtanen K, Ja¨rvinen A.
Comparison of sotalol and metoprolol in the prevention of atrial
fibrillation after coronary artery bypass surgery. J Cardiovasc
Pharmacol 1998;31:67–73, Matched ISSN: 0160-2446 (View via
PubMed) Linked.
25. Paull DL, Tidwell SL, Guyton SW, Harvey E, Woolf RA, Holmes
JR, et al. Beta blockade to prevent atrial dysrhythmias following
coronary bypass surgery. Am J Surg 1997;173:419–21, Matched
ISSN: 0002-9610 (View via PubMed) Linked.
26. Pfisterer ME, Klo¨ter-Weber UC, Huber M, Osswald S, Buser PT,
Skarvan K, et al. Prevention of supraventricular tachyarrhythmias
after open heart operation by low-dose sotalol: a prospective,
double-blind, randomized, placebo-controlled study. Ann Thorac
Surg 1997;64:1113–9, Matched ISSN: 0003-4975 (View via
PubMed) Linked.
27. Sanjua´n R1, Blasco M, Carbonell N, Jorda´ A, Nu´n˜ez J, Martı´nez-
Leo´n J, et al. Preoperative use of sotalol versus atenolol for atrial
fibrillation after cardiac surgery. Ann Thorac Surg 2004;77:838–43,
Matched ISSN: 0003-4975 (View via PubMed) Linked.
28. Shahzamani M, Ghanavati A, Froutagheh AN, Foroughi M,
Rahimian H, Shahsanaei A, et al. Carvedilol compared with
metoprolol on left ventricular ejection fraction after coronary
artery bypass graft. J Perianesth Nurs 2011;26:384–7, Matched
ISSN: 1089-9472 (View via PubMed) Linked.
29. Suttorp MJ, Kingma JH, Peels HO, Koomen EM, Tijssen JG, van
Hemel NM, et al. Effectiveness of sotalol in preventing supraven-
tricular tachyarrhythmias shortly after coronary artery bypass
grafting. Am J Cardiol 1991;68:1163–9, Matched ISSN: 0002-9149
(View via PubMed) Linked.
30. Suttorp MJ, Kingma JH, TjonJoeGin RM, vanHemel NM,
Koomen EM, Defauw JA, et al. Efficacy and safety of low- and
high-dose sotalol versus propranolol in the prevention of
supraventricular tachyarrhythmias early after coronary artery
bypass operations. J Thorac Cardiovasc Surg 1990;100:921–6,
Matched ISSN: 0022-5223 (View via PubMed) Linked.
31. Weber UK, Osswald S, HuberM, Buser P, Skarvan K, Stulz P, et al.
Selective versus non-selective antiarrhythmic approach for preven-
tion of atrial fibrillation after coronary surgery: is there a need for
pre-operative risk stratification? A prospective placebo-controlled
study using low-dose sotalol.Eur Heart J 1998;19:794–800,Matched
ISSN: 0195-668X (View via PubMed) Linked.
32. Yazicioglu L, Eryilmaz S, Sirlak M, Inan MB, Aral A, Tasoz R,
et al. The effect of preoperative digitalis and atenolol combination
on postoperative atrial fibrillation incidence. Eur J Cardiothorac
Surg 2002;22:397–401, Matched ISSN: 1010-7940 (View via
PubMed) Linked.
33. Omae T, Kanmura Y. Management of postoperative atrial
fibrillation. J Anesth 2012;26:429–37, Matched ISSN: 0913-8668
(View via PubMed) Linked.
34. Huang CX, Liu Y, Xia WF, Tang YH, Huang H. Oxidative stress:
a possible pathogenesis of atrial fibrillation. Med Hypotheses
2009;72:466–7, Matched ISSN: 0306-9877 (View via PubMed)
Linked.
96 M. Zeinah et al.35. Kumagai K, Nakashima H, Saku K. The HMG-CoA reductase
inhibitor atorvastatin prevents atrial fibrillation by inhibiting
inflammation in a canine sterile pericarditis model. Cardiovasc Res
2004;62:105–11, Matched ISSN: 0008-6363 (View via PubMed)
Linked.
36. Ozaydin M, Dogan A, Varol E, Kapan S, Tuzun N, Peker O, et al.
Statin use before by-pass surgery decreases the incidence and
shortens the duration of postoperative atrial fibrillation.Cardiology
2007;107:117–21, Matched ISSN: 0008-6312 (View via PubMed)
Linked.
37. Kalman JM, Munawar M, Howes LG, Louis WJ, Buxton BF,
Gutteridge G, et al. Atrial fibrillation after coronary artery bypassgrafting is associated with sympathetic activation. Ann Thorac
Surg 1995;60:1709–15, Matched ISSN: 0003-4975 (View via
PubMed) Linked.
38. McBride BF, White CM. Critical differences among beta-
adrenoreceptor antagonists in myocardial failure: debating the
MERIT of COMET. J Clin Pharmacol 2005;45:6–24, Matched
ISSN: 0091-2700 (View via PubMed) Linked.
39. Stroe AF, Gheorghiade M. Carvedilol: beta-blockade and beyond.
Rev Cardiovasc Med 2004;5(Suppl. 1):S18–27, Pathogenesis of
atrial fibrillation. Med Hypotheses 2009; 72: 466–467. Matched
ISSN: 0306–9877 (View via PubMed).
